What the FDA labels say about taking them together
Clopidogrel and daprodustat
Daprodustat's FDA label of August 30, 2023 names clopidogrel in its drug interactions section; the clopidogrel label PlainMeds reads does not name daprodustat. The daprodustat label: “Concomitant administration of moderate CYP2C8 inhibitors (e.g., clopidogrel) increases daprodustat exposure.”
Check it at the source: the clopidogrel FDA label on DailyMed (effective May 30, 2025, Sanofi-Aventis U.S. LLC); the daprodustat FDA label on DailyMed (effective August 30, 2023, GlaxoSmithKline LLC).
What does the clopidogrel label say about daprodustat?
Clopidogrel's label (effective May 30, 2025) does not name daprodustat in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (Plavix), Sanofi-Aventis U.S. LLC, effective May 30, 2025 (SPL set de8b0b67-eb25-4684-83b5-7ad785314227), via openFDA; the full label on DailyMed
What does the daprodustat label say about clopidogrel?
Daprodustat label, drug interactionsConcomitant administration of moderate CYP2C8 inhibitors (e.g., clopidogrel) increases daprodustat exposure [see Clinical Pharmacology ( 12.3 )].
Source: FDA drug label (Jesduvroq), GlaxoSmithKline LLC, effective August 30, 2023 (SPL set d82aa06e-5a33-4844-99b7-4701313455a4), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Clopidogrel | Daprodustat | |
|---|---|---|
| Labeled for | Heart attack and coronary artery disease, Angina | Anemia |
| Boxed warning | Yes | Yes |
| Pharmacy cost (NADAC) | $0.0472 per tablet 75 mg tablet | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once